Clinical efficacy of tirofiban combined with dual antibodies in the treatment of progressive stroke
替罗非班联合双抗治疗进展性脑卒中的临床效果

摘要

目的 开展替罗非班联合双抗治疗方案对进展性脑卒中患者的影响探析。方法 以2023年1月-12月时间段中于院内接受诊疗的进展性脑卒中患者为分析对象，共计95例，按照诊疗先后顺序设置成对照组（49例）、观察组（46例），两组分别行常规手段、替罗非班联合双抗治疗手段，对干预情况进行分析。结果 炎症指标及凝血指标方面，两组相比，治疗后观察组各项值更低（P<0.05）。FIM评分、MoCA评分、MMSE评分、Barthel指数等方面，两组相比，治疗后观察组各项值更高（P<0.05）。结论 在临床中实施替罗非班联合双抗治疗方案，能够对进展性脑卒中患者产生积极影响。

Abstract

Objective To explore the effect of Tirofiban combined with double antibody therapy on patients with progressive stroke.
Methods A total of 95 patients with progressive stroke who received diagnosis and treatment in hospital from January to December 2023 were selected as the analysis objects, and they were divided into control group (49 cases) and observation group (46 cases) according to the order of diagnosis and treatment. The two groups were respectively treated with conventional means and Tirofiban combined with double antibody treatment, and the intervention situation was analyzed.
Results The inflammation index and coagulation index of the two groups were lower than that of the observation group after treatment (P<0.05). FIM score, MoCA score, MMSE score and Barthel index were higher in the observation group after treatment than in the two groups (P<0.05).
Conclusion   The clinical implementation of Tirofiban combined with double antibody therapy can have a positive effect on patients with progressive stroke.